Related Experiment Videos
Innate immunity and atherogenesis.
M Rattazzi1, E Faggin, B Bertipaglia
1Dipartimento di Medicina Clinica e Sperimentale, Università di Padova, Treviso, Italy.
Lupus
|October 13, 2005
Summary
Atherosclerosis, the root of cardiovascular disease (CVD), is a chronic inflammatory process involving both innate and adaptive immunity. Understanding immune mediators may reveal new CVD risk factors and therapeutic targets.
Area of Science:
- Immunology
- Cardiovascular Science
- Pathology
Background:
- Atherosclerosis is the primary pathological basis for cardiovascular disease (CVD).
- Emerging evidence highlights atherosclerosis as a chronic inflammatory condition.
- Both innate and adaptive immune systems play active roles in atherogenesis.
Purpose of the Study:
- To explore the role of immune mediators in atherosclerosis.
- To investigate pattern-recognition receptors, cytokines, chemokines, and pentraxines in atherogenesis.
- To define the biological and clinical impact of these mediators on CVD.
Main Methods:
- Review of current scientific literature on immune involvement in atherosclerosis.
- Analysis of the roles of specific immune molecules like Toll-like receptors, IL-1, IL-6, TNFalpha, CRP, and PTX3.
- Exploration of emerging research in atherogenesis.
Main Results:
- Pattern-recognition receptors, cytokines (IL-1, IL-6, TNFalpha), chemokines, and pentraxines (CRP, PTX3) are implicated in atherogenesis.
- These immune mediators are integral to the inflammatory process underlying atherosclerosis.
- The precise biological and clinical significance of these mediators in CVD is under active investigation.
Conclusions:
- Immune mediators are crucial in the development of atherosclerosis.
- These mediators could enhance traditional risk factor assessment for CVD.
- Immune mediators represent potential novel therapeutic targets for CVD.